Akèy › Limfòm Non-Hodgkin › North Carolina
Etid klinik pou Limfòm Non-Hodgkin nan North Carolina
24 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 109, Greenville
- GC2202 Decentralized Study Site 114, Morrisville
- GC2202 Study Site 117, Wilson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05645107TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Atrium Health's Levine Cancer Institute, Charlotte
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Charlotte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558Pre-malignant States to Hematologic Malignancies in Firefighters
- Levine Cancer Institute, Charlotte
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 49 · Tout sèks · Mizajou Jul 13, 2026 · NCT06870760DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- ak 4 plis
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
Ap rekriteFaz 1
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Apr 13, 2026 · NCT01890486Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- ak 21 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Duke University Medical Center, Durham
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Duke University Medical Center, Durham
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- Carolina BioOncology, Huntersville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 4, 2026 · NCT05892718AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Duke University, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2025 · NCT06119685Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.